TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04154501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6016
Description: Oral Dose CNTX-6016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6016
Description: Oral Dose CNTX-6016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6016
Description: Oral Dose CNTX-6016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6016
Description: Oral Dose CNTX-6016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6016
Description: Oral Dose CNTX-6016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6016
Description: Oral Dose CNTX-6016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6016
Description: Oral Dose CNTX-6016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6016
Description: Oral Dose CNTX-6016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6016
Description: Oral Dose CNTX-6016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6016
Description: Oral Dose CNTX-6016

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Oral Dose Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Oral Dose Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Oral Dose Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Oral Dose Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Oral Dose Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Oral Dose Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Oral Dose Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Oral Dose Placebo
Study: NCT03885128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency extra thoracic oscillations vest
Description: Oscillations applied extra thoracic through vest device aiming for airway clearance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrathoracic oscillatory quake
Description: Oscillation introduced intrathoracic through quake device through placing quake in mouth and ordering patient to breathing to move secretions
Study: NCT00458731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study: NCT02491164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC TWO
Description: BAC TWO administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FE and Cellvizio viewer software
Description: Fibre based endomicroscopy to visualise fluorescent signal emitted by optical agents.
Study: NCT03368651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAI
Description: transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Study: NCT04752995

Intervention type: PROCEDURE
Group type: OTHER
Intervention: osteotomy
Description: osteotomy osteoclasis of upper tibia
Study: NCT01457742

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ivivi SofPulse
Description: 15 minute Pulsed Radio Frequency (PRF) treatment twice per day

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ivivi SofPulse
Description: 15 minute simulated treatment using Sham Device twice per day
Study: NCT02627495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS): (Soterix ©)
Description: Subjects will undergo tDCS stimulation. We will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated limb (or for bilateral amputees contralateral to the most painful side). The subject will undergo stimulation for 20 minutes. The subject will have 5 sessions of stimulation during a 1 week time period.
Study: NCT00880893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue vaccine
Description: 0.5 mL, Subcutaneous on Day 0, Months 6 and 12

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: NaCl + influenza virus or hepatitis A vaccine
Description: 0.5 mL, Subcutaneous (Intramuscular - Hepatitis A)
Study: NCT00479154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Maximum dose of 90 units/leg was injected.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum Toxin A
Description: Maximum dose of 90 units/leg was injected.
Study: NCT00510627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Description: The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Standard of care chemotherapy regimen
Study: NCT01099072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate+placebo
Description: methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)+ Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate+carnitine
Description: methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)+ Carnitine 500-1500 mg/day (depending on weight )
Study: NCT02229344

Intervention type: OTHER
Intervention: No Intervention
Description: Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
Study: NCT03754244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3456
Description: Observe the safety and pk when the subjects take TQB3456 p.o. qd
Study: NCT01540799

Intervention type: DEVICE
Group type: OTHER
Intervention: ATI Neurostimulation System
Description: ATI Neurostimulator (NS-100) and Remote Controller (RC-200)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATI Neurostimulation System
Description: ATI Neurostimulator (NS-100) and Remote Controller (RC-200)
Study: NCT03908619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20mg
Description: Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 20mg
Description: Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole Sodium 20mg
Description: Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
Study: NCT01179074

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oesophageal stenting with self expandable metal stent
Description: oesophageal stent placement for high grade dysphagia in inoperable oesophageal cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oesophageal stenting with self expandable metal stent
Description: oesophageal stent placement for high grade dysphagia in inoperable oesophageal cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oesophageal stent followed by external beam radiotherapy
Description: 30 Gy in 10 fractions over 2 weeks administered in the stent followed by EBRT group
Study: NCT04088344

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: isocaloric diet
Description: a 7-day isocaloric diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypercaloric diet
Description: A 7-day hypercaloric diet supplemented with carbohydrate-rich food (+ 50% of the subject's energy needs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid meal

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: PET imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perfusions of stable tracers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: perfusions of stable tracers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Indirect calorimetry
Study: NCT03405623

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic needle tip positioning under ultrasound-guidance
Description: The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional long-axis view
Description: The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
Study: NCT03639714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-C901
Description: a patient-specific neoantigen cancer vaccine prime

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-C901
Description: a patient-specific neoantigen cancer vaccine prime

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-R902
Description: a patient-specific neoantigen cancer vaccine boost

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-R902
Description: a patient-specific neoantigen cancer vaccine boost

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: anti-PD-1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: anti-PD-1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: anti-CTLA-4 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: anti-CTLA-4 monoclonal antibody
Study: NCT02323698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 30min after consumption to approximately coincide with peak plasma concentrations.Throughout the 30min wait time and experimentation, blood pressure and heart rate will be monitored.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 30min after consumption to approximately coincide with peak plasma concentrations.Throughout the 30min wait time and experimentation, blood pressure and heart rate will be monitored.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIH
Description: Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia). Throughout experimentation, blood pressure and heart rate will be monitored.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIH
Description: Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia). Throughout experimentation, blood pressure and heart rate will be monitored.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: This is a placebo counterpart to the caffeine drug. Subjects will ingest capsules containing dextrose. Experiments will begin 30min after consumption to mimic the caffeine drug protocol. Throughout experimentation, blood oxygenation, blood pressure and heart rate will be monitored.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SHAM
Description: This is a placebo counterpart to breathing intermittent low oxygen. Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
Study: NCT03678805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy
Description: Perforations in the areas close to the impacted canines will be performed in order to accelerate tooth movement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional withdrawal techniques
Description: The impacted canines will be withdrawn using elastic modules.
Study: NCT01762280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib Malate Capsule
Study: NCT01751217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Family Tx

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Family Tx

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Study: NCT02491814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1% M.F. Milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt Beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Beverage
Study: NCT04274998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NOS
Description: Main Study: PET/CT imaging will be used to evaluate neuroinflammation in the brain using the investigational radiotracer \[18F\]NOS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PBR28
Description: Sub-Study: Additional PET/CT imaging will be used to evaluate neuroinflammation in the brain for subjects with specific genetic polymorphism using the investigational radiotracer \[11C\]PBR28 in comparison to \[18F\]NOS.
Study: NCT00994344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Description: Darunavir/ritonavir 800/100 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir 400/100 mg twice daily
Study: NCT03704753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients (placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients (placebo).
Study: NCT02216110

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
Study: NCT03065972

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical fistula creation from patient's anatomy
Description: Patient will be randomized via computer system, to receive the fistula or graft. If fistula, surgeon creates fistula for hemodialysis access from patient's anatomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical fistula creation from patient's anatomy
Description: Patient will be randomized via computer system, to receive the fistula or graft. If fistula, surgeon creates fistula for hemodialysis access from patient's anatomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Graft implant
Description: Patient will be randomized via computer system, to receive the fistula or graft. If graft, surgeon implants hemodialysis access using an FDA approved graft.
Study: NCT04540016

Intervention type: DRUG
Group type: OTHER
Intervention: [14C]HSK7653
Description: 25 mg of \[14C\]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.
Study: NCT03664596

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sublimated mare's milk
Description: Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sublimated mare's milk
Description: Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).

Intervention type: DRUG
Group type: OTHER
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid in the form of 250 mg capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid in the form of 250 mg capsule.
Study: NCT00545272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Description: Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to indacaterol
Description: Placebo TWISTHALER® device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to indacaterol
Description: Placebo TWISTHALER® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short acting β2-agonist
Description: 100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short acting β2-agonist
Description: 100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short acting β2-agonist
Description: 100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short acting β2-agonist
Description: 100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short acting β2-agonist
Description: 100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: short acting β2-agonist
Description: 100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
Study: NCT04491604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Topical Beremagene Geperpavec
Description: Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching masked inactive topical gel
Study: NCT00586781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scandinavian Total Ankle Replacement (STAR)
Description: The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
Study: NCT00724867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Description: Belimumab 1 mg/kg IV over one hour every 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg IV over one hour every 28 days
Study: NCT02527603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Boss-Holzach-Matter method
Description: The patient holds both his hands around his knees in a supine position until the dislocated shoulder is reduced

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spaso method
Description: The physician holds the dislocated arm of the patient in a supine position and proceeds with gentle, soft movements of adduction, flexion and external rotation of the limb in this order until reduction is accomplished.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Inflammatory Agents, Non-Steroidal
Description: All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Inflammatory Agents, Non-Steroidal
Description: All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain.